Avaxia Biologics got patent for oral Anti-TNF antibodies for IBD
Avaxia Biologics, Inc., a clinical-stage biopharmaceutical company developing gut-targeted therapeutics, announced on 11th feb, 2014 that the company was awarded U.S. Patent No. 8,647,626, entitled “Compositions Comprising TNF-specific Antibodies for Oral Delivery.”